课题基金 / 基金详情

PHASE I STUDY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS USING SCH58500

PHASE I STUDY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS USING SCH58500
使用 SCH58500 对腹膜癌患者进行的 I 期研究
批准号：
6118455
负责人：
DENNIS J SLAMON
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118455
关键词：
antibody carcinoma clinical research clinical trial phase I gene mutation human subject human therapy evaluation neoplasm /cancer genetics neoplasm /cancer immunotherapy ovary neoplasms peritoneum neoplasm tumor suppressor genes

项目摘要

项目成果

DENNIS J SLAMON的其他基金

相似基金

相关文献

中文摘要
翻译
高达80%的卵巢癌患者的肿瘤表现出p53突变。 在卵巢肿瘤患者中发现大量p53抗体。 这一发现与p53基因突变的存在高度相关。 此外，特异性高（卵巢癌接近100%），但敏感性相当低（卵巢癌约为15%）。 p53基因突变的发生率与卵巢癌的恶性程度有关，且在卵巢癌中更为常见。
英文摘要
Up to 80% of ovarian cancer patients have tumors demonstrating p53 mutation. Antibodies to p53 are found in high numbers in patients with ovarian tumors. There was a high correlation of this finding with the presence of mutation for the p53 gene. In addition, the specificity was high (approaching 100% for ovarian cancer) but the sensitivity was quite low (approximately 15% for ovarian cancer). The incidence of p53 mutation has been correlated with the degree of malignant potential and was more commonly found in ovarian carcinoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Transcription Factor SLUG may Drive the Progression of Akt and HER2/neu
CRU - Clinical Research Unit Shared Resource
HER-2/NEU ALTERATIONS IN BREAST AND OVARIAN CANCER
PHASE I STUDY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS USING SCH58500
海外基金